'Official' 2009 Strategist S&P 500 Price Targets 13 comments
-
Font Size:
-
Print
- TweetThis
Below we list the 2009 S&P 500 strategist price targets in the final Bloomberg survey of 2008 (on 12/29). The average 2009 year-end S&P 500 estimate of the 11 sell-side strategists that participated is 1,056, or 16.9% above the S&P's year-end price of 903.25. UBS strategist David Bianco is the most bullish of the group with a year-end target of 1,300 (a 43.9% gain). Deutsche Bank's Binky Chadha is the second most bullish with a target of 1,140, followed by Goldman, Strategas, and JP Morgan, who are all looking for a gain of 21.8%. Only one strategist, Barclays' Barry Knapp, believes the S&P 500 will fall in 2009, but only by 3.2%.

The consensus estimate for year-end 2008 was 1,632 at the start of last year, which translated into an expected gain of 11.12%. Let's hope the strategists are a little closer to the mark this year.
Related Articles
|




























This article has 13 comments:
This article is useless. Who could possible even care about what these strategists think or predict? These are the same people, who were dead wrong last year.
It should be apparent to people (though it never appears to be) that these people have as much of a chance being right about the markets as the average american does.
I guess the only difference is, is that these strategists have somehow fooled enough smart people into thinking they should be grossly compensated for their useless wisdom.
Gosh I need a shower to rinse away all the filth every time I read about or see one of these strategists opinions.
Remember, the financial industry survives solely on convincing people that they know better than you. It is all interconnected. They scratch each others back when necessary to keep parting your hard earned money from you.
Hey it's capitalism sure, but better to be informed than outright taken advantage of.
The next big thing coming is stem cell based regenerative medicine, this is a huge field as big as TECHNOLOGY if not bigger. From the hardware(tools) to treatments to drugs, this is the golden opportunity for those who do some study, dig in further, a lot have been going on yet a lot more will be happening as the new year unfold especially in "adult stem cell area".
Investment in tools, treatments or drugs now is like investment in TECHNOLOGY a decade ago in hardware, software and internet/mobile.
Investment in tools is the safest and the 1st to be rewarded, then treatments and then in drugs. Treatments and drugs will have the biggest winfall but they are further down the pipeline in terms of timing.
Disclosure: long tool stock (KOOL), lurking on stocks in treatment and drug with stem cell/regentive medicine flavor.
The Market should lose a MINIMUM of 20% in 2009 if not more.
A 25 year credit bubble doesn't end this fast.
RBS also called the crash, sometime late summer
Who pays these clowns?